Peptide RX

back to claim graph

proof receipt / target

FGFR1

Fibroblast growth factor receptor 1

grade B status recovery receipt 639742cd69b7 proof 33%

what this node claims

FGFR1

Fibroblast growth factor receptor 1

Open source surface

vertical proof spine

  1. 01 FGFR1 target / grade B / 70% 1 debt
  2. 02 FGFR1-Selective PAM for Cartilage Anabolism idea / grade C / 55%
  3. 03 FGFR1 WT fold / grade B / 62% 2 debt

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 21%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    RTK
    functional sites
      gene symbol
      FGFR1
      go terms
        uniprot
        P11362

        AlphaFold metrics visual

        Confident backbone model

        73.8

        822 residues / min 21.48 / max 98.62 / source alphafold db

        PAE matrix for linked target
        Very high 33.5% 275 residues / >=90
        Confident 36.3% 298 residues / 70-89
        Low 6.9% 57 residues / 50-69
        Very low 23.4% 192 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 822 of 822 residues.

        • residues 398-464 / mean 33.32
        • residues 763-822 / mean 34.13
        • residues 120-148 / mean 39.06
        • residues 13-39 / mean 38.82
        proof debt register

        Visible limits, not hidden cleanup.

        21%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        idea names target idea:33ae8fee-a16a-4fd3-91fa-a6e3069e8aca -> target:ffdc4162-f8e6-4137-bee3-46bee6fceb6f targets / C / 0.44

        what it supports

        target has structure prediction target:ffdc4162-f8e6-4137-bee3-46bee6fceb6f -> fold:e7c03163-bcb0-4a18-be89-91202a050ecb folds_to / B / 0.738

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.